Drug Pipeline

REGN9933 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12

Active Studies

Recruiting

Phase 3

Top Sponsors

Changes, 30 Days

What Changed in the Last 30 Days

Detected	Trial	Change
2026-05-30	NCT07430956 Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation…	Trial sites expanded: 5 -> 13 locations
2026-05-23	NCT07318610 Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With…	Recruitment opened
2026-05-23	NCT07318610 Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With…	date change Primary completion pushed: 2029-05-05 -> 2029-08-18
2026-05-23	NCT07318610 Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With…	date change Completion pushed: 2029-08-03 -> 2029-11-16

Active Studies by Phase

Phase 3

Phase 2

Active Trials

NCT ID	Title	Condition	Status
Phase 3
NCT07318610	Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With…	Peripheral Artery Disease (PAD)	Recruiting
NCT07430956	Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation…	Atrial Fibrillation (AF)	Recruiting
Phase 2
NCT07175428	Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation	Atrial Fibrillation (AF)	Recruiting

Sponsors Running REGN9933 Trials

Regeneron Pharmaceuticals (3)

Disease Areas

Atrial Fibrillation (2)

Get alerts when REGN9933 trials change

Status changes, date slips, and new filings — detected daily, delivered to your inbox.